Published in Haematologica on November 10, 2009
Beta-thalassemia. Orphanet J Rare Dis (2010) 3.06
The life of patients with thalassemia major. Haematologica (2010) 1.12
Pregnancy Outcomes in Women with Homozygous Beta Thalassaemia: A single-centre experience from Oman. Sultan Qaboos Univ Med J (2014) 0.90
Reproductive capacity in iron overloaded women with thalassemia major. Blood (2011) 0.83
Beta-thalassemia major and female fertility: the role of iron and iron-induced oxidative stress. Anemia (2013) 0.83
Regional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf area. Orphanet J Rare Dis (2013) 0.79
Guidelines for the Standard Monitoring of Patients With Thalassemia: Report of the Thalassemia Longitudinal Cohort. J Pediatr Hematol Oncol (2015) 0.78
Endocrine and bone complications in β-thalassemia intermedia: current understanding and treatment. Biomed Res Int (2015) 0.76
Pregnancy in women with thalassemia: challenges and solutions. Int J Womens Health (2016) 0.75
Autologous blood reservation is vital for pregnant patient with intermediate thalassemia. Adv Biomed Res (2015) 0.75
Cyclosporine therapy during pregnancy in a patient with β-thalassemia major and autoimmune haemolytic anemia: a case report and review of the literature. Hippokratia (2013) 0.75
Pregnancy outcomes in women with thalassemia in North America and the United Kingdom. Am J Hematol (2013) 0.75
Marital Status and Fertility in Adult Iranian Patients with β-Thalassemia Major. Indian J Hematol Blood Transfus (2015) 0.75
A successful twin pregnancy in a patient with HbE-β-thalassemia in western India. J Postgrad Med (2015) 0.75
Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica (2006) 3.81
Complications of beta-thalassemia major in North America. Blood (2004) 2.97
Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2008) 2.85
A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis (2005) 2.15
Intrauterine restriction (IUGR). J Perinat Med (2008) 1.72
Endocrine complications in patients with Thalassaemia Major. Pediatr Endocrinol Rev (2007) 1.25
When does mother to child transmission of hepatitis C virus occur? Arch Dis Child Fetal Neonatal Ed (2005) 1.14
Pregnancy outcome in patients with beta-thalassemia intermedia at two tertiary care centers, in Beirut and Milan. Haematologica (2008) 1.13
Fertility in thalassemia: the Greek experience. J Pediatr Endocrinol Metab (1998) 1.10
Update on fertility in thalassaemia major. Pediatr Endocrinol Rev (2004) 1.09
Deferoxamine treatment during pregnancy: is it harmful? Am J Hematol (1999) 1.04
Update on thalassemia: clinical care and complications. Pediatr Clin North Am (2008) 0.94
Beta-thalassemia syndromes and pregnancy. Obstet Gynecol Surv (1994) 0.93
Rapid iron loading in a pregnant woman with transfusion-dependent thalassemia after brief cessation of iron chelation therapy. Eur J Haematol (2008) 0.92
Fertility and pregnancy in thalassemia major. Ann N Y Acad Sci (2005) 0.92
Pregnancy management and outcomes in women with thalassaemia major. J Pediatr Endocrinol Metab (1998) 0.87
Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns. Am J Hematol (2006) 0.87
Pregnancy in patients with well-treated beta-thalassemia: outcome for mothers and newborn infants. Am J Obstet Gynecol (1999) 0.87
Reproductive health in individuals with homozygous beta-thalassemia: knowledge, attitudes, and behavior. Fertil Steril (2002) 0.85
A thalassemic child becomes adult. Rev Clin Exp Hematol (2003) 0.85
Pregnancy in patients with beta-thalassaemia major: maternal and foetal outcome. Acta Haematol (2008) 0.84
Successful pregnancy in a patient with thalassaemia major. J Obstet Gynaecol Br Commonw (1969) 0.81
High-risk pregnancy in beta-thalassemia major women. Report of three cases. Gynecol Obstet Invest (2000) 0.80
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood (2005) 6.07
Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med (2012) 5.87
Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A (2008) 5.27
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica (2004) 5.21
Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging (2011) 4.78
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica (2008) 2.92
Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol (2008) 2.82
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood (2005) 2.75
Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica (2005) 2.64
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica (2006) 2.54
Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica (2005) 2.53
Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica (2007) 2.52
Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet (2011) 2.51
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood (2005) 2.45
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology (2004) 2.41
On T2* magnetic resonance and cardiac iron. Circulation (2011) 2.33
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica (2008) 2.29
Beta-thalassemia. Genet Med (2010) 2.24
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica (2006) 2.14
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Purging iron from the heart. Br J Haematol (2004) 2.07
Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. J Clin Oncol (2014) 2.04
Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet (2009) 1.87
Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation (2009) 1.85
Thalassemia. Hematology Am Soc Hematol Educ Program (2004) 1.83
Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int (2004) 1.78
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood (2002) 1.77
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol (2007) 1.77
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson (2008) 1.76
KLF1 gene mutations cause borderline HbA(2). Blood (2011) 1.71
In vitro mass production of human erythroid cells from the blood of normal donors and of thalassemic patients. Blood Cells Mol Dis (2002) 1.70
Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis (2002) 1.63
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma (2011) 1.60
Mutational spectrum in congenital dyserythropoietic anemia type II: identification of 19 novel variants in SEC23B gene. Am J Hematol (2010) 1.60
Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart (2012) 1.56
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica (2008) 1.54
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma (2007) 1.54
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood (2014) 1.54
The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart (2011) 1.52
Screening for thalassemia: a model of success. Obstet Gynecol Clin North Am (2002) 1.50
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood (2012) 1.49
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood (2003) 1.46
Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol (2003) 1.46
Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol (2011) 1.45
The relation of ventricular arrhythmia electrophysiological characteristics to cardiac phenotype and circadian patterns in hypertrophic cardiomyopathy. Europace (2011) 1.41
Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. Br J Haematol (2014) 1.40
Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging (2012) 1.40
Left ventricular noncompaction in patients with β-thalassemia: uncovering a previously unrecognized abnormality. Am J Hematol (2012) 1.39
A valine deletion of ferroportin 1: a common mutation in hemochromastosis type 4. Blood (2002) 1.31
Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica (2004) 1.30
Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica (2008) 1.24
Electrophysiological abnormalities precede overt structural changes in arrhythmogenic right ventricular cardiomyopathy due to mutations in desmoplakin-A combined murine and human study. Eur Heart J (2012) 1.24
Compound heterozygosity for KLF1 mutations associated with remarkable increase of fetal hemoglobin and red cell protoporphyrin. Haematologica (2011) 1.23
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol (2009) 1.23
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood (2011) 1.23
Pathophysiology of beta thalassaemia. Pediatr Endocrinol Rev (2011) 1.22
Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol (2004) 1.22
Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord (2011) 1.21
The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol (2002) 1.21
Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood (2005) 1.17
High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol (2009) 1.16
International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging (2010) 1.14
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann N Y Acad Sci (2005) 1.14
Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol (2003) 1.13
Changes in the quality of life of people with thalassemia major between 2001 and 2009. Patient Prefer Adherence (2013) 1.13
A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica (2006) 1.13
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res (2011) 1.12
Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. Heart (2011) 1.11
Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation (2013) 1.11